AR039194A1 - FORMULATION OF STABILIZED NATURAL CANNABINOIDS - Google Patents

FORMULATION OF STABILIZED NATURAL CANNABINOIDS

Info

Publication number
AR039194A1
AR039194A1 ARP030101107A ARP030101107A AR039194A1 AR 039194 A1 AR039194 A1 AR 039194A1 AR P030101107 A ARP030101107 A AR P030101107A AR P030101107 A ARP030101107 A AR P030101107A AR 039194 A1 AR039194 A1 AR 039194A1
Authority
AR
Argentina
Prior art keywords
sugar
mixture
glass
formulation
cannabinoid compound
Prior art date
Application number
ARP030101107A
Other languages
Spanish (es)
Inventor
Anco C Eissens
Drooge Dirk J Van
Wouter L J Hinrichs
Henderik W Frijlink
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of AR039194A1 publication Critical patent/AR039194A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende un compuesto cannabinoide natural, por ejemplo delta9-tetrahidrocannabinol, y un vidrio de un azúcar de alcohol de azúcar, de mezcla de azúcares o de mezcla de alcoholes de azúcares, caracterizado porque el compuesto cannabinoide natural está incorporado en el vidrio de azúcar como una encapsulación monomolecular sin formación de un complejo huésped-hospedante. Un método para la preparación de dicha composición farmacéutica en la forma de un vidrio de azúcar mediante secado por congelamiento, secado por rociado, secado al vacío, o secado en condiciones críticas de una mezcla estable que contiene el compuesto cannabinoide natural y un azúcar o una mezcla de azúcares.Pharmaceutical composition comprising a natural cannabinoid compound, for example delta9-tetrahydrocannabinol, and a glass of a sugar of sugar alcohol, of a mixture of sugars or of a mixture of sugar alcohols, characterized in that the natural cannabinoid compound is incorporated in the glass of sugar as a monomolecular encapsulation without formation of a host-host complex. A method for the preparation of said pharmaceutical composition in the form of a sugar glass by freeze drying, spray drying, vacuum drying, or drying under critical conditions of a stable mixture containing the natural cannabinoid compound and a sugar or a mixture of sugars

ARP030101107A 2002-04-03 2003-03-28 FORMULATION OF STABILIZED NATURAL CANNABINOIDS AR039194A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36961302P 2002-04-03 2002-04-03
EP02076339 2002-04-04

Publications (1)

Publication Number Publication Date
AR039194A1 true AR039194A1 (en) 2005-02-09

Family

ID=42777215

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101107A AR039194A1 (en) 2002-04-03 2003-03-28 FORMULATION OF STABILIZED NATURAL CANNABINOIDS

Country Status (3)

Country Link
KR (1) KR100976073B1 (en)
AR (1) AR039194A1 (en)
TW (1) TWI332406B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation

Also Published As

Publication number Publication date
TW200403078A (en) 2004-03-01
TWI332406B (en) 2010-11-01
KR20040095362A (en) 2004-11-12
KR100976073B1 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
HK1078458A1 (en) Stabilized natural cannabinoid formulation and the prepation method thereof
AR052787A1 (en) PROCESS TO PREPARE FORMULATIONS OF LIPOFILIC ACTIVE SUBSTANCES THROUGH ATOMIZATION LIOPHILIZATION
ATE430560T1 (en) FORMULATION FOR RAPID DISSOLUTION OF LIPOPHILIC COMPOUNDS
AR073009A1 (en) PRODUCTION, FORMULATION, AND USES OF FORMULATIONS OF HARPINA PROTEIN STABLE LIQUIDS
CL2010000816A1 (en) Formulation suitable for subcutaneous administration comprising at least 100 mg / ml of ctlaig, a sugar, and a pharmaceutically stable aqueous carrier; article of manufacture comprising at least one container containing the aforementioned formulation. (divisional application n ° 3597-06)
CL2003002048A1 (en) WATER SOLUBLE GRANULAR COMPOSITION THAT INCLUDES AT LEAST 40% OF A PLANT GROWTH REGULATOR, AN ADHERENT, A DISCARD AND A SURFACTANT, WHERE THE PLANT GROWTH REGULATOR IS ESPECIALLY A GIBERELINE, PROCEDURE FOR
GT199900203A (en) CELECOXIB COMPOSITIONS.
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
PT1187601E (en) NEW FORM OF PREPARATION AND ADMINISTRATION UNDERSTANDING AN INHIBITOR OF THE PUMP INSTABLE INSTABLE IN MEDIUM ACID
CR8480A (en) VETERINARY FORMULATIONS CONTAINING NON-ANIMAL PRODUCT
BR112013004865A2 (en) lipids suitable for liposomal delivery of rna protein coders
EA018545B1 (en) Therapeutic compositions
AR085989A2 (en) ENDOPARASITICIDE COMPOSITIONS AND PROCESS FOR PREPARATION
AR055561A1 (en) TABLETS WITH IMPROVED DISPERSION OF PHARMACOLOGICAL SUBSTANCE
WO2009107983A3 (en) Stabilized single-liquid pharmaceutical composition containing docetaxel
BRPI0413957A (en) process for preparing water soluble diterpenes, aqueous solution and their applications
AR032872A1 (en) COMPOSITION TO CLEAR THE SKIN AND APPLICATION METHOD
AR036887A1 (en) DEVICE FOR RELEASE OF SUBSTANCES.
BRPI0407652A (en) method for enhancing the effectiveness of an active agent, composition and method for producing the composition
BR0107899A (en) Process for producing an active ingredient preparation comprising ibuprofen, preparation of active ingredient, use thereof, pharmaceutical preparation, use thereof, process for producing solid dosage forms, and, solid dosage form
AR036357A1 (en) COMPOSITION OF ENDOPARASITICIDE GEL, A METHOD FOR PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR064263A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMPOSITE BISFOSFATO
ECSP034718A (en) PARASITICIDE COMPOSITIONS AND METHODS OF USE
BRPI0511387A (en) composition and its use
PA8548301A1 (en) PHARMACEUTICAL FORMULATION OF MASKED FLAVOR AND PROCEDURE FOR PREPARATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure